Handelsavisen
prelaunch
Companies Healthcare IDXG.PK
ID
IDXG.PK OTC Pharmaceutical Services

Idxg.Pk

$1,55
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
10,5 %
ROE
109,9 %
Net margin
63,5 %
Debt / equity
0,00
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
2026-10-28
Ex-dividend
TR 1Y
About

IDXG operates in the healthcare sector, focusing on pharmaceuticals and healthcare facilities and services.

Business. IDXG operates in the healthcare sector, focusing on pharmaceuticals and healthcare facilities and services.

Classification99 %
SectorHealth Care
Industry groupPharmaceutical Services
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
109,9 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning IDXG.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to IDXG.PK. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    IDXG operates in the healthcare sector, focusing on pharmaceuticals and healthcare facilities and services.

    Classification99 %
    SectorHealth Care
    Industry groupPharmaceutical Services
    AI synthesis
    GENERATED

    IDXG maintains a strong liquidity position, with a current ratio of 1.94, indicating the company can cover its short-term liabilities with its short-term assets. The company has no long-term debt, and its cash and equivalents amount to $2.5 million, contributing to a debt-to-equity ratio of 0.0. This suggests a conservative capital structure with no leverage, which is uncommon in the healthcare sector where debt is often used to finance growth.

    In terms of profitability, IDXG's return on equity (ROE) is 1.0989, and its return on assets (ROA) is 0.7263. These figures are relatively high compared to the typical performance metrics in the healthcare facilities and services industry, where ROE and ROA are often lower due to the capital-intensive nature of the sector. The company's net income of $24.58 million on revenue of $38.73 million indicates a strong bottom-line performance.

    IDXG's revenue is concentrated in a single business segment, as disclosed in its financials, with no geographic diversification provided in the available data. This lack of segment and geographic diversification could pose a concentration risk, as the company's performance is tied to a single operational area.

    The company's growth trajectory is not explicitly outlined in the available data, but its strong free cash flow of $25.05 million and operating cash flow of $5.83 million suggest a solid cash-generating ability. These figures indicate that the company is in a position to reinvest in its operations or return value to shareholders, although no specific growth initiatives or capital allocation plans are disclosed.

    Risk factors for IDXG are minimal, with no immediate liquidity or dilution flags detected. The company's low debt and strong cash position reduce financial risk, and there is no indication of dilution pressure from recent filings or transcripts. However, the absence of long-term debt could also limit the company's ability to finance expansion or strategic acquisitions.

    Recent events, including filings and transcripts, do not show any material developments that would significantly impact IDXG's operations or financial position. The company appears to be in a stable financial condition with no immediate concerns highlighted in its disclosures.

    Key takeaways
    • IDXG has a strong liquidity position with a current ratio of 1.94 and no long-term debt.
    • The company's ROE and ROA are relatively high, indicating strong profitability.
    • IDXG's revenue is concentrated in a single segment, which could pose a concentration risk.
    • The company generates significant free cash flow, suggesting a strong cash-generating ability.
    • There are no immediate liquidity or dilution risks, and the company's financial position is stable.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $1,55
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $22.4M
    Net cash
    $2.5M
    Current ratio
    1.9
    Debt / equity
    0.0
    ROA
    72.6%
    ROE
    1.1%
    Cash conversion
    24.0%
    CapEx / revenue
    -0.9%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    INDUSTRYSEGMENTCOMPANYHealthcareIndustryPharmaceutical Services41,1B node revenuePHG 49,5%EHC 14,5%BKD 7,8%TDOC 6,2%HIMS 5,7%NTRA 5,6%NHC 3,7%PNTG 2,3%Other 4,8%
    Source: company disclosures · own-taxonomy revenue-covered setIDXG 0,1% · rank #17 of 18

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    Peer comparison8 peers · vs IDXG · multiples and returns
    PH
    PHG
    PHG.BK
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    EH
    EHC
    Encompass Health Corp
    $112,47
    11,5B USD
    P/E
    18,6x
    vs self
    Div yield
    0,6 %
    vs self
    ROE
    23,2 %
    vs self
    BK
    BKD
    Brookdale Senior Living Inc
    $14,37
    3,4B USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    469,6 %
    vs self
    TD
    TDOC
    TELADOC HEALTH, INC.
    $6,57
    1,2B USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    -14,5 %
    vs self
    HI
    HIMS
    Hims & Hers Health Inc
    $25,20
    5,8B USD
    P/E
    48,1x
    vs self
    Div yield
    vs self
    ROE
    23,7 %
    vs self
    NT
    NTRA
    NATERA, INC.
    $270,36
    38,6B USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    -8,5 %
    vs self
    NH
    NHC
    National Healthcare Corp
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    PN
    PNTG
    Pennant Group Inc
    $40,18
    1,4B USD
    P/E
    39,2x
    vs self
    Div yield
    vs self
    ROE
    8,1 %
    vs self

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin10,5 %Above P75
    Net Margin63,5 %Best in class
    ROE109,9 %Best in class
    Capex / Rev-0,9 %Above median
    D/E0,00Above median
    Cash Conv0,24Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • IDXG.PK Market data — financials · 2026-05-28

    Ownership & reference

    Leadership

    • Thomas W. BurnellPresident, Chief Executive Officer, Director

    Insider activity

    — missing data

    Short positioning

    455shares short+48.7% vs prior
    1days to cover
    90fails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    IDXG.PKCanonical
    OTC · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    • Gross profit (YoY) (2025-12-31 vs 2024-12-31): -19.4%Derived (calculated)
    • Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 25.5%Derived (calculated)
    • Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -32.5%Derived (calculated)
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): 128.8%Derived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 1,108.7%Derived (calculated)
    • Revenue (YoY) (2025-12-31 vs 2024-12-31): -17.5%Derived (calculated)
    • Net income (YoY) (2025-12-31 vs 2024-12-31): 266.7%Derived (calculated)
    • Operating income (YoY) (2025-12-31 vs 2024-12-31): -49.6%Derived (calculated)
    • EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 122.5%Derived (calculated)
    • Net margin (FY 2025-12-31): 63.5%Derived (calculated)
    • Gross margin (FY 2025-12-31): 62.3%Derived (calculated)
    • Return on equity (FY 2025-12-31): 109.9%Derived (calculated)
    • Return on assets (FY 2025-12-31): 72.6%Derived (calculated)
    • Current ratio (FY 2025-12-31): 1.94xDerived (calculated)
    • Debt-to-equity (FY 2025-12-31): 0.51xDerived (calculated)
    • Capex (YoY) (2025-12-31 vs 2024-12-31): -59.4%Derived (calculated)
    • R&D expense (YoY) (2025-12-31 vs 2024-12-31): -5.0%Derived (calculated)
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 71.5%Derived (calculated)
    • EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 290.8%Derived (calculated)
    • Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): -14.1%Derived (calculated)
    • Cash & equivalents (annual): USD 2.5MSEC XBRL filing
    • Shareholders' equity (annual): USD 22.36MSEC XBRL filing
    • Gross profit (annual): USD 24.13MSEC XBRL filing
    • Operating cash flow (annual): USD 5.83MSEC XBRL filing
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage